1. Home
  2. SCYX vs NTZ Comparison

SCYX vs NTZ Comparison

Compare SCYX & NTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • NTZ
  • Stock Information
  • Founded
  • SCYX 1999
  • NTZ 1959
  • Country
  • SCYX United States
  • NTZ Italy
  • Employees
  • SCYX N/A
  • NTZ N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • NTZ Home Furnishings
  • Sector
  • SCYX Health Care
  • NTZ Consumer Discretionary
  • Exchange
  • SCYX Nasdaq
  • NTZ Nasdaq
  • Market Cap
  • SCYX 34.9M
  • NTZ 31.2M
  • IPO Year
  • SCYX 2014
  • NTZ 1993
  • Fundamental
  • Price
  • SCYX $1.10
  • NTZ $3.80
  • Analyst Decision
  • SCYX
  • NTZ
  • Analyst Count
  • SCYX 0
  • NTZ 0
  • Target Price
  • SCYX N/A
  • NTZ N/A
  • AVG Volume (30 Days)
  • SCYX 204.1K
  • NTZ 3.3K
  • Earning Date
  • SCYX 11-05-2025
  • NTZ 10-21-2025
  • Dividend Yield
  • SCYX N/A
  • NTZ N/A
  • EPS Growth
  • SCYX N/A
  • NTZ N/A
  • EPS
  • SCYX N/A
  • NTZ N/A
  • Revenue
  • SCYX $3,257,000.00
  • NTZ $337,653,480.00
  • Revenue This Year
  • SCYX $422.61
  • NTZ N/A
  • Revenue Next Year
  • SCYX $240.56
  • NTZ N/A
  • P/E Ratio
  • SCYX N/A
  • NTZ N/A
  • Revenue Growth
  • SCYX N/A
  • NTZ N/A
  • 52 Week Low
  • SCYX $0.66
  • NTZ $2.15
  • 52 Week High
  • SCYX $1.66
  • NTZ $6.27
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 71.20
  • NTZ 67.51
  • Support Level
  • SCYX $0.81
  • NTZ $2.94
  • Resistance Level
  • SCYX $1.31
  • NTZ $3.50
  • Average True Range (ATR)
  • SCYX 0.07
  • NTZ 0.17
  • MACD
  • SCYX 0.03
  • NTZ 0.09
  • Stochastic Oscillator
  • SCYX 58.33
  • NTZ 80.88

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About NTZ Natuzzi S.p.A.

Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.

Share on Social Networks: